After High Court, SuperValu's $123M FCA Case Heads To Trial

SuperValu is bound for trial in February over whistleblower claims that it billed the government higher-than-customary prices for millions of prescriptions, marking an important test of a recent U.S. Supreme Court...

Already a subscriber? Click here to view full article